文献速递肝病消化道肿瘤与早癌

NAFLD患者肝细胞癌筛查的合理策略

Rational HCC screening approaches for patients with NAFLD.
PubMed 文献 · J Hepatol · 2021-09-09

非酒精性脂肪性肝病(NAFLD)与肝细胞癌(HCC)风险增加相关,尤其合并肝硬化或进展性纤维化者,但20-30%的NAFLD相关HCC发生于无进展性纤维化者。全球多数国家NAFLD相关HCC患病率上升。缺乏直接数据支持或反驳HCC监测在NAFLD中的疗效或有效性,本文基于其他疾病的监测证据和NAFLD临床病程研究提出合理筛查建议,并指出研究与实践空白。

要点

  • NAFLD相关HCC可发生于无进展性纤维化者,占20-30%。
  • 全球多数国家NAFLD相关HCC患病率呈上升趋势。
  • 缺乏直接证据支持NAFLD中HCC监测的疗效,需借鉴其他疾病证据。

核心结论

  • NAFLD相关HCC风险增加,尤其肝硬化或进展性纤维化者,但20-30%病例无进展性纤维化。
  • 缺乏直接数据支持或反驳NAFLD中HCC监测的疗效或有效性。
  • 基于其他疾病监测证据和NAFLD临床病程研究提出合理筛查建议。

研究设计与样本

  • 本文为综述,基于其他疾病的监测证据和NAFLD临床病程研究提出建议。

主要发现

  • NAFLD相关HCC中20-30%发生于无进展性纤维化者。
  • 全球多数国家NAFLD相关HCC患病率上升。

临床怎么用

  • 对NAFLD患者应基于现有证据考虑HCC监测,尤其肝硬化或进展性纤维化者。
  • 需关注无进展性纤维化NAFLD患者的HCC风险。

局限性

  • 缺乏直接数据支持或反驳NAFLD中HCC监测的疗效或有效性。
  • 存在研究与实践空白。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of developing hepatocellular carcinoma (HCC), especially among those who have cirrhosis or advanced fibrosis, but 20-30% of cases of NAFLD-related HCC occur in the absence of advanced fibrosis. The prevalence of NAFLD-related HCC is increasing in most countries worldwide. There are few direct data to support or refute the efficacy or effectiveness of HCC surveillance in NAFLD or to guide its application. We use evidence on surveillance in other conditions and studies on the clinical course of patients with NAFLD to arrive at recommendations for rational approaches to HCC surveillance in this growing cohort of patients. We also outline gaps in research and practice, including opportunities to advance the field.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Singal AG, El-Serag HB. Rational HCC screening approaches for patients with NAFLD. J Hepatol. 2021. PMID: 34508791. doi:10.1016/j.jhep.2021.08.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。